Results 121 to 130 of about 1,484,561 (230)

Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)

open access: yes, 1999
Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type ...
Pollanen,, Jari   +20 more
core  

RERF Conformational Preferenc from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung metastasis

open access: yes, 2009
RERF Conformational Preferenc from Structure-based design of an urokinase-type plasminogen activator receptor–derived peptide inhibiting cell migration and lung ...
Mario De Rosa (15040481)   +12 more
core   +1 more source

Supplementary Figure 1 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells

open access: yes, 2010
Supplementary Figure 1 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft ...
Jeffrey D. Klopfenstein (7925075)   +9 more
core   +1 more source

Supplementary Figure 3 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells

open access: yes, 2010
Supplementary Figure 3 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft ...
Jeffrey D. Klopfenstein (7925075)   +9 more
core   +1 more source

INDUCTION AND/OR MAINTENANCE OF TUMOR DORMANCY BY DISRUPTION OF UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-INTEGRIN INTERACTION

open access: yes, 2010
The present invention relates to a method of inducing cancer cells into dormancy and treating cancer in a subject. This method involves administering to a subject an effective amount of a compound that disrupts interaction between urokinase plasminogen ...
Aguirre-Ghiso Julio, A   +4 more
core  

Soluble urokinase plasminogen activator receptor - What are the clinical potentials in psychiatry? [PDF]

open access: yesBrain Behav Immun Health
Huber FG   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy